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AN EXCURSION INTO PHARMACOLOGY:
CURARE IN MEDICINE
by
RANYARD WEST*
INTRODUCTION
IN our present age of specialization, it is not easy to move from one branch of
medical study to another in pursuit ofa single piece ofresearch, a singleenquiry.
Fifty years ago, Sir Thomas Lewis wrote that on occasion it may be desirable for
the clinical scientist to become his own pharmacologist. And fifty years ago, the
present writer, a clinician, made an excursion into pharmacology in pursuit of an
elusive quarry, curare as a therapeutic agent.
At that time, pharmacology was a somewhat different discipline from what it is
today: the whole animal was, I think, used more; its organs were stimulated and
records taken in situ: the smoked drum was still in evidence. The course and methods
of pharmacology that we had followed as students could come back readily to hand
ten years later, particularly if, as was our custom in London, the budding clinician
paved his way to recognition by "demonstrating" for a time in the physiology or other
scientific department of his hospital medical school. Though problems might be
clinical, the laboratories were there and welcoming. We did not feel it a foreign excur-
sion to get into them in order to try to solve our problems.
Curare first became a therapeutically effective agent during the 1940s, when A. E.
Bennett and his colleagues introduced it as a modifying agent in electropexy,l and
Griffith and Johnson first exhibited it as an anaesthetic adjuvant.2 A third use in
medical practice arose during the 1950s, when Lassen and his colleagues, having
established the treatment ofacute poliomyelitis, realized that acute tetanus poisoning
could be effectively handled by the same means -that is, by tracheostomy and positive
pressure respiration, with the administration ofd-tubocurarine intravenously to allay
the tetanic convulsions.3
For curare to become established successfully in each of these three fields, certain
pre-conditions were required. First, a stable preparation of curare had to be secured,
of constant action and constant strength, and free from unfavourable or uncontroll-
able side-actions. The drug had to be available in adequate quantities; and a
satisfactory means of artificial respiration was necessary. With the exception of posi-
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tive pressure respiration, these conditions were made possible by work done earlier,
particularly during the previous decade, the 1930s.
As a clinician, my own interest in the "taming"ofcurare arose in a peculiar way. An
unusual case of what was then sometimes known as "neurological tetany" - a
characteristic "tetany" spasm and posture without the characteristic chemical
serological changes4-had led me to embark upon a somewhat ambitious investigation
into the neurological mechanism of tetany, studying this in the tetany produced by
parathyroidectomy in dogs.5
For this work, Hamilton Hartridge, then professor of physiology at St
Bartholomew's Hospital, London, kindly gave me facilities in his laboratory, and also
made the following suggestion: "Before you interrupt any nerve pathways surgically,
why not try curare? It will paralyse the nerve-endings, and tell you whether the spasms
oftetany constitute a purely muscular phenomenon, or not".
THE LISSIVE EFFECT*
At that time (1929), curare consisted of lumps of a thick, black, toffee-like sub-
stance. It reached the museums and laboratories ofthecivilized world through traders
and explorers, who obtained it in hollowed gourds, earthenware pots ofvarying sizes,
orbamboo tubes, from one or other ofits remote South American sources.
Hartridge and I performed the suggested experiment together, using a crude curare
which we obtained from Burroughs Wellcome & Co., who had bought it in Paris. We
fully expected the result to show one oftwo things, either (1) a paralysis ofthe dog by
curarization without removal of its tetany, or (2) a paralysis ofthe dog with removal
of its tetany. We were startled to find that the tonic, clonic, and fibrillary muscular
contractions characteristic of the tetany were all removed, and the musculature
returned to seemingly normal function-all in response tosub-paralyticdoses ofcurare
- indeed, with a dosage so low as to leave the animal with apparently full motor
power. Serum calcium estimations were made and did not change: the recovery was
therefore not due to a chemical removal of the tetany, such as happens if parathor-
mone is administered.'
This was the basis ofour drive for curare, its alkaloids, and their differential phar-
macology, in 1930. The clinical possibilities were exciting. For there were no drugs
available to relax the spasticities of hemiplegia and paraplegia with which our
neurological wards and out-patients were crowded. A clinical trial of crude curare
appeared to me to bejustified; and, once ourfindings in dog-tetany werepublished, we
received a number ofkind gifts ofcurare to this end. We obtained further supplies by
purchase. The curares were all tested on frogs, small mammals, and dogs. The results
set us our next problem.
Of seven specimens ofcrude curare that came to us, only two showed the selective
4R. West, 'Pituitary cyst', ibid., 1931,11: 69-71.
I R. West, 'Studies in neurological mechanism ofparathyroid tetany', Brain, 1935, 58: 1-20.
6H. Hartridge and R. West, 'Parathyroid tetany in dogs, and its abolition by curare', ibid., 1931, 54:
312-319.
*"Lissive" means "selectively removing rigidity".
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relaxation of the muscles of a dog in tetany. One of these was the gift of Sir Charles
Sherrington at Oxford; it was obtained in a native earthenware pot and thus was pre-
sumed to have come from the Orinoco river area of Venezuela. The other was the
curare from an unknown source that we had obtained through Burroughs Wellcome.
Our communication of this differential finding followed hard upon the heels of the
first announcement ofthe lissive effect with which we had been so pleased.7
Hartridge and I now found ourselves faced with the long-standing puzzles of the
chemistry and pharmacology ofcurare. These were problems not to be quickly solved.
Meanwhile, I set up a cautious clinical trial, in the first place of the two curares that
had given good results in dog tetany. Burroughs Wellcome kindly filtered and
sterilized these curares, and put them up in glass ampoules, as a clear brown liquid.
I was fortunately placed for undertaking this research. It was before the inception
of the British National Health Service, in the heyday of the dominance of the
voluntary hospitals. Upon such research no legal restrictions were placed: there was
no Dunlop Committee. I was able to use cases at the Hospital for Nervous Diseases
at Maida Vale, where I was then a medical registrar; at the National Hospital for
Nervous Diseases at Queen Square, through the courtesy of Dr Arnold Carmichael,
recently appointed by the Medical Research Council as director ofresearch there; and
from late in 1929, I had, in addition, my own beds at the Seamen's Hospital at
Greenwich, into which I was permitted to admit cases (to beds not required for
seamen) for research purposes. Commencing with very small doses, and never increas-
ing the dose by more than fifty per cent of the previously ineffective dose, I injected
subcutaneously the sterile curare extracts. Dosage was calculated from our dog doses.
In this series of patients, which included five cases of pyramidal spasticity and four
cases of extra-pyramidal (Parkinsonian) rigidity, Sherrington's curare was used
throughout. The rigidities relaxed selectively in all cases, though the tremor of
Parkinson's disease might concomitantly increase. Improvement could usually be
maintained with the pyramidal tract spasticities: the Parkinsonian post-encephalitics
usually ended by preferring one of the then regularly used drugs, scopolamine,
stramonium, or atropine. The periods of relaxed muscle tone facilitated physical
treatment where this was helpful. I published my results," which certainly suggested
that something in some curares might have a place in our scanty armamentarium for
treating chronic nervous disease.
Further shocks were in store for us, however, as Hartridge and I began to examine
the various other curares that came to our laboratory. In 1930, curare was available in
considerable quantity - when looked at in terms offrog dosage, as it then was by most
physiologists. But for use in large animals, or in man, these quantities were small. The
material was also unreliable. We found that the content of a gourd pot, or bamboo
might prove to be a powerful curare poison; or it might readily cause strychnine-like
convulsions with varying or no paralytic action being present. Or, again, the
specimen might prove to be practically, or entirely, inert.
Neither were supplies to be depended upon. It seemed doubtful whether curare
was produced anywhere in the world at that time. The results of our early
7Ibid., p. 508.
R. West,'Curare in man', Proc. R. Soc. Med., 1932,25:1107-1116.
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enquiries, and our rough preliminary chemical and pharmacological investigations,
showed that we had a long way to travel. We needed expert chemistry. I needed to
know more pharmacology. Finally, we needed plant material, to discover what plants
should be searched for, and whither an expedition in search of plant ingredients of
curare could best be sent, or encouraged to go. At this stage (1931), the problem ofthe
chemistry ofcurare and the question ofexpeditionary help were inter-related. Ideally,
so it seemed to me, we should try to find a clearly lissive curare (or obtain from a
curare a lissive chemical fraction), become aware of the geographical source of that
curare, and institute plant collections in that region.
Sir Charles Sherrington's specimen suggested the Orinoco basin geographically: it
was where pot curare usually came from. I accordingly reported our success with
Sherrington's pot curare to Dr J. W. Trevan of the Wellcome Physiological
Research Laboratories. I also told him of the confusing pharmacological actions we
were beginning to meet with, and repeated to him a comment made to us by W. E.
Dixon, veteran pharmacologist at Cambridge, to the effect that we should find that
curare could "act on sympathetic ganglia, as well as on motor nerve endings". I think
it was the first time any of us had heard this: it foreshadowed the "nicotine-like"
action I was frequently to encounter in later fractions. Dr Trevan told me that the
Wellcome Laboratories had already received further supplies of curare, again, he
thought, "from France". He promised me further autoclaved material, and said he
"would try to isolate curarine". As regards an expedition, his commercial firm,
Burroughs Wellcome, had asked a research expedition of theirs, about to depart for
the Amazon, to try "to get the secret ofthe curare plant" from the natives.
By this time I was also in touch with Sir Walter Fletcher, secretary to the Medical
Research Council. I held Sir Thomas Lewis's view that the clinical scientist may
usefully make himself "his own pharmacologist". For the chemistry of curare we
must have an expert. But I had in mind to learn the necessary pharmacology myself.
Sir Walter Fletcher volunteered that Dr H. H. Dale could probably give me space for
dogs at the Medical Research Council's laboratory at Hampstead. I did not take this
up at once. With a Londoner's desire to escape from London, I preferred to stay on at
Barts for the time being, in the hope that a period at Oxford might fit into my
programme later on. But shortly afterwards, Sir Walter Fletcher wrote to me that
"some of these questions relating to curare ought to be taken up seriously and early;
and I should beglad ifyou would talk this over with Dr Dale".
So, to Hampstead, and my first personal experience of H. H. (later Sir Henry)
Dale. He showed immediate grasp ofthe whole problem. Not only did he approve of
my clinical trials of curare, but he suggested that the veteran Henry Head, who was
then severely stricken with paralysis agitans, might like to be treated with curare, as a
pioneer, in line with his earlier heroic sensory-nerve section on himself. This proposal
did not materialize. Whatever Head himself may have thought, the idea was rejected
by his own clinical neurologist, properly, at that stage, I thought. Dale also took up
the chemical problem. To my delight, he said he would not wait for plants, but get to
work on the crude curare, and "could put a chemist onto it right away, ifhe had a free
hand". He did not, however, wish "to interfere with any work already started
elsewhere in response to your enthusiasm"!
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Early in November 1931, I received a copy ofTrevan's definitive reply to questions
asked him by Sir Walter Fletcher on behalf of the Medical Research Council.
Burroughs Wellcome would not go ahead chemically until they could obtain "the
plant concerned"; and their present expedition, already at Manaus, had reported that
a proper search required a larger expedition than they had mounted, and one prepared
to "go some distance into the very dangerous and unsettled interior". Trevan had pre-
viously confided to me his opinon that "Dale will get out the alkaloids if we don't";
and, further, that "curare may well be where ergot was before Dale took it up". Since
Dale had been eminently successful with ergot, this looked like business!
Of the traditional curare regions of South America, British Guiana was
undoubtedly the region most easily approached from Britain: we had a competent
colonial administration there. From a clinical point of view, the pot curare areas of
the Orinoco basin were at once most desirable and most elusive: Sherrington's pot had
yielded a lissive curare. So, too, had Burroughs Wellcome's curare from an unknown
source. It came to us from Paris: it might well be Amazonian, and therefore of bamboo
(tube) origin. Amazonia at first appeared a hopeful possibility for collection of
material: and I was fortunate in finding in the British Museum a good, well-labelled
specimen ("Ucayali River, 1871"), inside its bamboo tube. I was still more fortunate
in being allowed to abstract a portion and take it to my chemical collaborator, Harold
King (see below) who was most fortunate in being able to extract from it his first pure
dextro-tubo-curarine chloride.9 But that was in 1935, and I have anticipated.
By enquiry from the secretary of the Royal Geographical Society, I learned in the
autumn of 1931 of two imminent expeditions to the Amazon basin. Dyott, a well-
known explorer, wrote that he "could, perhaps, collect curare, but not plants".
Professor J. W. Gregory ofGlasgow, a geologist, was to leave early in the New Year
on a canoeing expedition down the Amazon from very high up the Ucayali branch. I
saw Gregory, and he promised to keep a bright look-out: "but I shall be travelling
very fast". Sadly, he was drowned during the course ofhis descent. A colleague wrote
later that no curare had been met with by the expedition.
With the Orinoco, the region associated with Sherrington's lissive pot curare, no
link was obtainable. Nor did King succeed in supplying me with a lissive fraction from
our limited supply ofpot curare. This created a gap in our knowledge which was never
filled.
We settled then, for British Guiana, I communicating directly with key local
figures, the Medical Research Council supporting us through the usual, but powerful,
governmental channels.
BOTANY AND FIELD WORK
The colony of British Guiana enjoyed an efficient forestry service. Early in 1932,
their assistant conservator of forests, T. A. Warren Davis, returned from an expedi-
tion into the interior of the colony made from his station on the Mazaruni river. An
object ofthe expedition had been the collection ofrare plants.
N. Y. Sandwith, of the Royal Botanic Gardens, Kew, described this expedition as
9 H. King, Nature, Lond., 1935, 135: 460.
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"a very important one".'0 Nine different species of strychnos plants were collected,
three of which were traditionally associated with native preparations of curare: (i)
Strychnos cogens, a rarely collected specimen, in scant supply, but repeatedly
mentioned by the famous botanists, Richard and Robert Schomburgk, and identified
by the latter as the effective ingredient of "cumarawa", an alternative poison, the
native Indians said, to curare (or "urari") proper; (ii) S. toxifera, theeffective agent in
the curare prepared by the Macusi Indians, and widely distributed in British Guiana
and elsewhere; (iii) S. pedunculata, which, as "Yakki", provided a further, and
perhaps alternative, ingredient of "Macusi" curare. This strychnos was rediscovered
by Davis during this expedition; but, like S. cogens, was only obtainable in small
quantities, suitable for botanical identification, but insufficient for chemical or phar-
macological assay.
Shortly after shipping this consignment ofbotanical specimens to Kew Gardens, the
conservator of forests was, at our instigation, and through the good offices of the
Medical Research Council and the colonial governor, requested to send a further
expedition into the interior of British Guiana in order to collect S. toxifera in quantity
sufficient for chemical analysis, and also to make substantial collections ofthe bark of
any other plants likely to be associated with curare. The response from the colony was
excellent: and very soon fine quantities of strychnos bark reached my laboratory (by
now at Oxford). One consignment of S. toxifera weighed eighty pounds. In all cases,
duplicate botanical specimens were sent to Kew Gardens for identification.
It transpired, as one might have guessed, that the colonial forestry department, and
particularly an officer as keen as Warren Davis proved to be, already knew a great
deal about plant material in the region, and its native associations. Davis's knowledge
ofhabitat, and his experience in collecting rare species for and with N. Y. Sandwith in
an earlier expedition (1929)" - one in which S. diaboli (Sandwith) was obtained for
the first time - made him just the explorer-botanist we needed. The only trouble was
that, in the three subsequentjourneys Davis made on our behalf, he would have liked
to go farther than the budgets ofhis department allowed. To his great regret, he was
never able to collect S. cogens in quantity sufficient for chemical and pharmacological
trial by us. I do not know if it has even now been collected in quantity sufficient for
adequatechemical analysis or full pharmacological appraisal.
Meanwhile, as a result ofhis expedition of 1932, Warren Davis collected, packaged,
and shipped to us, four species ofstrychnos, and one rubiaceous plant, all in quantities
that sufficed for the alkaloidal material to be extracted and its reactions tested
pharmacologically.'2"3 Where suitable, the effects of these alkaloids upon spastic
disease werealso observed.'3
10N. Y. Sandwith, Kew Bulletin, 1933, no. 7 and no. 8, p. 395.
N. Y. Sandwith, ibid., 1931, p. 486.
12 R. West, 'Pharmacology and the therapeutics ofcurare and itsconstituents', Proc. R. Soc. Med., 1935,
28: 565-578.
13 R. West, 'A pharmacological study ofderivatives oftwo specimens oftubo-curare and an examination
of four members of genus strychnos and one rubiaceous plant associated with the curares of British
Guiana', Arch. internat. Pharmacodyn. Therap., 1937, 56: 81-116.
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CHEMISTRY AND PHARMACOLOGY
As prospective chemical collaborator, Dale introduced me to Harold King of his
laboratory staff. King was a very experienced alkaloidal chemist whose interest in the
purification ofcurares was easily aroused in thecontext ofDale's own current work on
neuromuscular transmission by acetylcholine, which transmission curare inhibits.
King and I worked in close collaboration through the six years 1932-37. His many
chemical fractions were all examined pharmacologically by me.
First of all, and while I was still with Hartridge in London, King and a gifted
medical student, A. Stephens, fractionated the various crude curares that we had
accumulated;'2 though for their preparation for human clinical trials I still relied on
the Wellcome Laboratories. Later, and largely after I had moved to Oxford, King
supplied me with samples of all the alkaloidal material that could be extracted from
the barks shipped to us from Guiana -a very considerable chemical task."
In January 1934, I moved into Professor J. A. Gunn's pharmacology department at
Oxford. Gunn invited me to demonstrate for him, gave me splendid laboratory
facilities, and taught me how to recognize (and where possible assay) the various
actions of the curare fractions King was producing - all except curare bronchospasm,
in which my expert helper was K. J. Franklin, the senior demonstrator, and later
professor ofphysiology at Barts.
I was anxious not to deepen a rut produced by thirty years ofLondon life; and I had
quite deliberately approached Oxford on this matter of location. My own hospital
beds, and my main access to neurological beds, were in London and must not begiven
up. But to work directly under the Medical Research Council I should have had to
cross central London daily from my home at Blackheath in the south to Hampstead in
the north; and this did not appeal. Pharmacology now occupied very much ofmy time:
a quiet, sequestered laboratory, such as Gunn ruled over at Oxford, was just what I
needed. I was delighted when the message came, and I could be out of the bustle of
London for the major part of the week. It was an arrangement that lasted for four
years.
Hartridge was most generous about my move to Oxford. A great mechanist,
Hartridge always had many enterprises awaiting his skilful intervention. But he had
enjoyed our amateur attack upon curare; and between 1930 and 1932, he designed for
me two "automatic rheotomes" for measuring electrical reactions, and a simple but
effective apparatus for measuring and recording spasticity.8 He surrendered his
amateur chemistry to King with perfect grace. He kindly allowed me to continue to
use his laboratory at Barts for my work with dogs and parathyroid tetany, which was
not completed until 1935.S
By the time King's chemical work on the curare plants began to come to hand at
Oxford, I had become accustomed to some ofthe actions to beexpected. I kept hoping
that a single alkaloid would be obtained pure, and that it would exhibit a lissive effect
in spastic diseases in man. It was the removal ofhuman rigidities that I sought; though
a separation in favour of the dog-tetany was not without interest, for it might
indicate a mixture of central- and peripherally-acting drugs (or actions), and so
become adjustable for therapeutic use in man.
In pharmacology, Gunn's help was minimal, but definite and authoritative. He
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would push up his spectacles, peer at the twitching frog, and ejaculate: "Nicotine! Try
it on the vagus ganglion!". The senior "lab. man", Long, assisted me, and would
know how to do the experiment. I was no longer on my own.
It is unnecessary to detail the pharmacology ofthe consignments that arrived from
Guiana, sometimes in my laboratory, sometimes in Harold King's, between 1932 and
1937. Details are to be found in our published papers. 12, '3A briefsummary follows.
In this account I have already mentioned that the pharmacology of our various
crude curares had proved most variable. In the event I found that an alleged "curare"
might be found to contain (1) a curariform action, (2) a nicotine-like action (more
prominent with some curares than others, and never found alone), (3) a central
nervous excitant (strychnine-like) action, sometimes more prominent than its
curariform effect, (4) a central nervous depressant action, seldom prominent, and (5)
in curares containing S. toxifera - and in general in calabash curare - a bronchocons-
trictor action.
King obtained d-tubocurarine pure in 1935,9 and I recorded its pharmacology
then.'2 As for the alkaloidal plant extracts, most of them impure, with which King
provided me, the actions of the various extracts comprised, between them, the phar-
macological effects listed above.'3 Semi-crystalline (calabash) curarine, and the pure
alkaloid, diaboline, deserve special mention, though the reactions of the former are
now familiar.
Curarine has a curarizing action stronger than that of pure d-tubocurarine. It also
has a bronchoconstrictor action which is delayed, even in the isolated tracheal ring of
the cat,'3 and is believed to be due to the liberation ofhistamine.'4 The pharmacology
ofdiaboline is described under S. diabolibelow.
The pharmacology of the more important barks (stem-barks, I think, in all cases),
collected by Davis, and chemically extracted by King, may be summarized as follows:
1. S. toxifera. Considerable quantities of bark from Guiana enabled King to supply
curarine for assay, for trial in tetanus, and to send to chemists abroad. In treating
tetanus, I was forced to use curarine as the only alkaloid then available; d-
tubocurarine, though isolated, remained in very short supply, its plant source still
unknown. The unfortunate tendency of curarine to produce or facilitate broncho-
spasm led me to issue warnings against its general clinical use.'5
2. S. erichsonii showed a preponderance of a convulsant - strychnine-like - action.
This was accompanied by a curarizing action and a nicotine-like stimulation of
respiration and intestinal movements. Extracts were lissive in dog-tetany. But they
increased, rather than diminished, the spasticity ofone case ofparaplegia. Work on
the alkaloids ofthis strychnos was accordingly abandoned.'3
3. 5. diaboli. Extracts were similar in action to those ofS. erichsonii, with the addition
of a depressant action on the central nervous system. Spinal cord excitation was
active, though delayed. The extracts weregiven intramuscularly or intravenously.'3
From S. diaboli, a pure alkaloid diaboline was obtained by King in 1936, and
examined by me at the time. It was described by Dr Boris Krukoffofthe New York
Botanical Garden as being the "first pure alkaloid to be obtained from a South
14 West, op. cit., note 13 above, pp. 88, 114.
" R. West, 'Intravenous curarine in thetreatment oftetanus', Lancet, 1936, i: 12-16.
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American strychnos".16 Both the chemistry and the pharmacology ofdiaboline are
interesting, and perhaps important. Chemically, diaboline is related to strychnine,
through the Wieland-Gumlich aldehyde.'7"8 Pharmacologically, it has, in addition
to a weak curare action, a delayed strychnine-like action in mammals. In man,
diaboline increased spasticity in a single case ofspastic paraplegia, but it was lissive
in dog-tetany.l3*
4. Guettarda acreana, (native name "Yakki"), though not a strychnos, is an alleged
constituent of"Macusi" curare, and was found to have the same series ofactions as
diaboline. Its alkaloids were all presented in non-quaternary form. The rigidity ofa
case of spastic paraplegia was increased by a dose of 2mgm per kilo of a fresh
extract ofthe plant.'3
These results were full of hints, but offered nothing tangible. They represented our
results in 1937, after four years' work and three expeditions into the interior of British
Guiana. Naturally, I was disappointed. Were we to give up, or to try again? We had
no plan for collecting plant material from the Amazon areas, whence we thought had
come one ofour lissive curares, and certainly the tubocurarine that King had isolated.
Nor had we penetrated the upper Orinoco basin, the probable origin ofSherrington's
pot curare, which I had found lissive in man. We had not even combed the Guianese
curare areas thoroughly. S. pedunculata and S. cogens, towards which Davis had fre-
quently cast his eye, lay farther afield, probably in the region of the Kanaku or
Pakaraima mountains, but involving a four to six months' long expedition which
might cost £800 or more. The Medical Research Council were not prepared to meet
such expense.
Reviewing my correspondence with Harold King, I see that 1936 was a very busy
year, I chivvying, he patient, if occasionally expostulatory! I had plenty of phar-
macology to do on King's many fractions, but no new successes in treating human
spasticities to report. Looking back, I think I over-estimated the degree to which
those in authority on the Medical Research Council staff shared my enthusiasm. I
alone was in personal touch with the officers concerned in British Guiana. Sir Walter
Fletcher, reinforced by Sir Henry Dale's interest in the chemical side ofthe work, had
merely asked the colonial government to assist us. No financial support had been
offered to the colony, which considered itself a poor one; and its government was
inclined tojib at the idea of repeated medical research expeditions paid for by itself!
This I learnt from the forest officers concerned.
Authority, whether in office or laboratory, could hardly be expected fully to share
my point of view. My enthusiasm was clinically based: I had seen and measured the
relaxing spastic limb muscles. The fact that King had isolated pure d-tubocurarine
from a bamboo curare which came from the upper Amazon tended to lessen rather
than increase the interest of chemists in plant collection from another area, such as
British Guiana. With the exception of S. toxifera, which Davis was able to collect in
quantity, and which yielded much to King, and also, eventually, to Wieland and his
16 B. A. Krukoff, Memoirs ofthe New York Botanical Gardens, 1965, 12(2): 37.
7 A. R. Battersby and H. F. Hodson, Proc. Chem. Soc., April 1959, p. 126.
" A. R. Battersby, J. Chem. Soc., 1960, 216: 736.
*See below, pp.404-405.
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colleagues in Germany,19 there were only my faint hopes to hold attention on the
botany of our own colony. S. diaboli and diaboline did not greatly interest British
chemists at that time.
King himself always responded to my enthusiasm, though to respond involved
boiling up endless frothy plant extracts with low alkaloidal contents, in deference to
my hope that they containedjust the right ingredient to cure my patients. Davis alone
shared my enthusiasm. He thought he knew where S. cogens and S. pedunculata were
to be found; and he regarded several months' hard labour as an exploring botanist as
an entirely reasonable price to pay for the hopes that such a prize aroused. Twice he
wrote hoping I would come out andjoin him on the trip. I considered that I ought to
stay at home.
The year 1936 brought our first news that others were at work on curare plant
collections. Sandwith at Kew heard from his opposite number, A. C. Smith, at the
New York Botanical Gardens, that Boris Krukoff had gone afield in search, among
other plants, of S. diaboli. Krukoff was at that time collecting for Merck Inc. This
search was consequent upon the announcement ofourcrystallization ofdiaboline, and
its described pharmacology.20 King did not, however, publish his chemical
characterization of diaboline until 1949,21 though my pharmacological account has,
through Krukoff,"6 given him his priority. Dr Krukoff goes on to record his opinion
that "the intensive search forStrychnos" in thegreat basin oftheAmazon "all started
with N.Y. Sandwith's brief paper in which he describes S. diaboli, and King and
West's work on its bark".1' This is the botanist speaking! But a wider view of the
historical record would have to ask what aroused the interest of Drs Major and
Molitor of Merck Research Laboratories, and induced them to commission Dr
Krukoff"to investigate and obtain authentic materials ofplants entering thecurare of
the Tecuna Indians ofBrazil" -this in June 1935.
Harold King's letter to Nature of March 1935' had announced at once his intended
broad chemical survey of curare, our assembly ofcurare plants from British Guiana,
the lissive action of some crude curares - which it is true, had appeared in 1932 - and
his own isolation ofd-tubocurarine from crude bamboo curare (certainly Brazilian in
origin). These facts would be likely to interest Merck Inc.
Again, King and I would never have come together to work on S. diaboli without
the drive for lissive material and curare chemistry of ourselves severally, and the
botanical associations (field and specialized) that had brought Sandwith and Warren
Davis together in Guiana, able to forward us appropriate and ample supplies. It was a
widely collaborative effort in which King and I clearly traded a chemist's search for
purity against a clinician's search for therapy. I continue to hope that our association
has left a useful residuum for continuing enquiry.
TETANUS
While a number of chronic nervous diseases would benefit from a selective relaxa-
tion of tonic muscular spasm which left voluntary power intact, tetanus was an acute
19 H. Wieland, K. Bahr, and B. Witkop, Ann. Chem., 1949,547:173.
20 B. A. Krukoff, personal communication, 1963.
21 H. King,J. Chem. Soc., 1949, 205: 955.
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disease that cried out to be treated by a muscle relaxant, while antitoxin dealt with its
toxaemia.
Following the work of Claude Bernard (1856), which clarified its physiology, the
use ofcurare in tetanus and hydrophobia was many times heroically attempted; but all
attempts to establish a method of treatment were dogged by the unreliability of
action ofthe preparations available and the difficulties ofartificial respiration, ifthat
had to be resorted to. Over the years, reports came from many countries, and included
well-known names: Benjamin Brodie (who preceded the main Bernard and Kolliker
publications) in 1839, Vulpian (Paris) in 1857, Sayre (New York) in 1858, Spencer
Wells (London) in 1859, to mention just a few of the pioneers. Throughout the
nineteenth century, abortive efforts to arrest tetanic convulsive spasms with curare
were made, again and again, particularly in Germany and France.22
During the 1920s and 1930s, acute tetanus was rife in certain areas of Britain,
including the fen district of East Anglia. L. B. Cole, physician to Addenbrooke's
Hospital, Cambridge, took a special interest in this distressing disease. In an
investigation published in 1934,23 Cole used a gourd (calabash) curare, successfully, in
an acute case, with an incubation period of only seven days and a consequently poor
prognosis. The treatment was supplementary to full dosage of antitoxin, and a
supporting regimen which he had built up over the years. He was able to secure a good
curare ofhigh potency, but noted with regret the absence of a standard preparation of
known composition. Again, in 1935, Cole published a full review of twenty-one cases
oftetanus treated since 1927, in three ofwhich he had used calabash curare.24 In 1969,
he again reviewed the position ofthe treatment oftetanus, after present-day treatment
had become established.23
One other British physician treated a case of tetanus with curare at that time. In
1934, Dr (now Professor) J. S. Mitchell, when a house-physician in Birmingham,
treated a boy of sixteen suffering from acute tetanus with a nine-day incubation
period, with one injection of 0.5 mgm of a crude curare, followed by injections of a
"curine-free curarine" obtained from a Berlin source. 0.1 mgm of the curarine was
administered four hourly, subcutaneously, and the dose increased slowly and experi-
mentally until eight doses of 0.5 mgm were given per diem, 48 mgm in all being given
during twenty days (calabash curarine is considerably more potent than d-
tubocurarine). Antitoxin 70,000 units i.v., and avertin anaesthesia were given on the
first day. There was marked decrease in muscular rigidity from the very first; and.the
patient recovered - a most successful outcome.26
Between 1934 and 1937, I was able to see and treat a considerable number of
patients suffering from very severe tetanus. In 1936, I described ten cases,'5 all ofthem
treated with curare or curarine, three of them with curarine given intravenously. In
22 A. R. McIntyre, Curare: its history, nature, and clinical use, Chicago, University of Chicago Press,
1947; K. Bryn Thomas, Curare - its history and usage, London, Pitman Medical Publishing Co., 1964.
23 L. Cole, 'Tetanus treated with curare', Lancet, 1934, ii: 475-477.
24 L. Cole and E. T. C. Spooner, 'Treatment of tetanus, with observations on fate of injected antitoxin',
Quart.J. Med., 1935, 4(15): 295-319.
25 L. Cole and H. Youngman, 'Treatment oftetanus', Lancet, 1969, i: 1017-1019.
26 J. S. Mitchell, 'A case oftetanus treated with curare', ibid., 1935, i: 262-264.
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this series, fulminating cases were especially asked for and selected, cases in which "a
fatal prognosis can be made with little hope oferror".27 Thanks to Davis's response in
collecting S. toxifera bark in bulk, King had been able to give me plenty ofcurarine -
Boehm's curarine - stable, constant in dose and action, but never a quite pure sub-
stance. Bronchospasm, sufficient to require intubation, occurred from time to time.
This was not only a feature ofthe treatment oftetanus: it occurred even in one case of
Parkinsonism.28
This tendency ofcalabash curarine to produce bronchospasm was, however, doubly
dangerous in treating tetanus. No doubt it was associated with inadequate oxygena-
tion; but we had no sure means ofovercoming it. Drinker respirators and Bragg-Paul
pulsators were tried and found unsuitable (the Nuffield iron lung was not yet
invented). I found a neat French transfusion pump, made by Henry and Jouvelet, that
secured a steady intravenous inflow ofcurarine: a cam "milked" a thick rubber tube,
slowly and irresistibly, into the vein. This, combined with a two-way endotracheal
catheter, was as far as'we got in the right direction! Routine tracheostomy did not
occur to me: intermittent positive pressure remained in the future (though we had it
for animals in the laboratory). Here, above all, I ought to have sought the aid of
Hamilton Hartridge, who faced with any mechanical problem "saw likely paths to
answers wherever he turned".29 Regrettably, I did not do so.
Results were accordingly disappointing: respiratory distress always intervening to
baffle us. In the end, I concluded that "the only present place for intravenous curarine
in therapeutics is its continued experimental use in cases of tetanus in which, by the
accepted standards (Cole, 1935) recovery cannot be expected by other means".'5 A
comparison of this report in the Lancet of 1936 with a case recorded in the same
journal in 195630 shows well the progress effected in the treatment of tetanus during
those twenty years. In my hands, the effects ofcurarine on the physiology of respira-
tion was disastrous to its use in tetanus.3' Subsequently, curare bronchospasm was
shown by Landmesser to occur also with d-tubocurarine, though less readily than
with curarine.32"33
I had only been able to find so many cases ofacute tetanus by advertising for them.
This I did by writing to strictly professional medical journals, the Lancet27 and the
British MedicalJournal.34 To do so, was, however, considered to be a somewhat unusual
procedure, a rather personal advertisement. My circumstances were themselves
unusual. Unlike thegeneral pattern then followed by honorary physicians on the staffs
of voluntary hospitals, I was dependent, financially, not upon any private consulting
practice, but upon a Beit Memorial Research Fellowship. Dale agreed that the matter
was important; and no direct objection was ever raised by medical colleagues to this
27 R. West, letter to Editor, ibid., 1934, ii: 1416.
28 R. West, 'The action ofcurarine in respiration', ibid., 1938, i: 432-433.
29 W. A. H. Rushton, 'Hamilton Hartridge FRS', Biogr. Mem. Fellows R. Soc. Lond., 1977.
30 A. C. Smith, E. E. Hill, and J. A. Hopson, 'Treatment ofsevere tetany', Lancet, 1956, ii: 550-552.
31 R. West, 'Action ofcurarine on respiratory mechanism', J. Physiol., 1938, 91: 437-446.
32 C. M. Landmesser, 'Study of bronchoconstrictor and hypotensive actions of curarizing drugs',
Anaesthesiology, 1947, 8: 506-523.
33 C. M. Landmesser, J. G. Converse, and M. H. Harmel, 'Quantitative evaluation ofbronchoconstrictor
action ofcurare in anaesthetized patient', ibid., 1952, 13: 275-280.
34 R. West, letter to Editor, Br. med. J., 5 March 1935.
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unusual method ofcollecting cases for research. At the time, I was rather proud of it!
I suggested that a central repository of clinical research requirements might be
established. Those were theearly days ofclinical research as such.
Unfortunately for me, I had reckoned without the sensational nature ofthe subject
and its consequent interest to the press. "Arrow poison to cure disease" was one
caption that I remember. The hospitals to which I was called - once by Radio S.O.S. -
collected reporters, requests for interviews, and, at night - even in those days - the
flash of lights for press cameras. I protested." Not only did I suffer this direct
nuisance over a considerable period ("Death's door doctor fails again"!), but I also
received a letter from Professor T. R. Elliott, the secretary of the Beit Fellowship
trustees, to tell me that one trustee had enquired how it was that a single fellow's name
was so constantly appearing in the press, since "the Beit Advisory Board are firmly
opposed to unusual statements in the lay press". Elliott, in accepting my explanation,
wrote: "I hope thesejournalistic devils will be foiled in any further attempt with your
name. The onlyway is to give them no information at all." Wise words!
LATER WORK AND FUTURE POSSIBILITIES
We had won something. Curarine, or, better, d-tubocurarine, might perhaps be
made effective in tetanus. But spastic disease awaited a lissive curare, thechemistry of
which was quite obscure. For work on spasticity, I thought our botanical net should
have been wider, and we should have been prepared to extend it further still. King had
produced d-tubocurarine from crude bamboo curare, which was known to have come
from Amazonia where we had no exploring agents, though we might possibly have
linked up with the Americans, who had; and we also had diaboline, which was ofgreat
interest to me then, and which later excited the interest of both Swiss and British
workers.
After 1937, it was the response of American chemists and explorers that led to
further progress in curare therapy. Soon (1938-43), Chondrodendron tomentosum
would be brought back to the United States from Amazonia by Richard Gill36 and
identified as the source ofd-tubocurarine by the work ofKrukoffand Moldenke,37 and
Wintersteiner and Dutcher.3J
In 1937, I abandoned curare research, my mind a turmoil oftheoretical considera-
tions about the interplay of central nervous excitant, and neuromuscular blocking
actions, but with little hope ofany early unravelling ofthe mysteries involved
The missing strychnos plants from Guiana were all found in the end, though years
later. In 1954, Davis's successor, D. B. Fanshawe,39 collected S. pedunculata in the
Kanuku mountains and S. cogens in the Pakaraima foothills. Both contained
alkaloids with a curare-like action. Fanshawe also re-collected S. mitscherlichii, in
which King found two alkaloids. From the same species, collected this time in Brazil,
35 R. West, letter to Editor, Lancet, 25 May 1935.
36 R. C. Gill, White waterand black magic, London, Gollancz, 1941.
37 B. A. Krukoffand H. N. Moldenke, Brittonia, 1938, 3: 1.
31 0. Wintersteiner and J. D. Dutcher, 'Curare alkaloids from Chondrodendron tomentosum', Science,
1943, 97: 467-470.
39 D. B. Fanshawe, Brittonia, 1954, 8: 65.
403R. West
Marini-Bettolo and his Italian colleagues40 later characterized five, and Karrer,
Schmid et al.,41 in Switzerland, six alkaloids. Diaboline was fully and most interest-
ingly defined by Battersby and Hodson, 17,18 as also by Karrer and Schmid.42 No
differential pharmacology is anywhere reported. The era of the clinically interested
pharmacologist was not, even yet, established. Or, perhaps, supplies still proved
insufficient for this sort ofpharmacology to be undertaken. However, the chemistry of
the curare alkaloids was much advanced; and the advance was fully recorded in
1959.43
As in the past, so in the future, the chemistry and pharmacology and therapeutics of
curare can profitably proceed hand in hand. Chemistry may differentiate clearly
between pharmacological actions, and pharmacology may detect specific effects that
prove to be ofvalue to medicine. In whatever way it comes about, the advent ofa drug
of a truly therapeutic lissive effect in spastic disease - one that will abolish
pathological rigidity of muscle and at the same time permit voluntary contraction to
take place - this is a desideratum as great in 1984 as it was in 1932. One may perhaps
speculate on how this could come about.
A single plant, in yielding a single alkaloid, can certainly provide a strong and reli-
able curare action. Chondrodendron tomentosum and Strychnos toxifera have both
done so; and as a result we have had d-tubocurarine and toxiferine and its derivatives
available commercially for many years.
Can a single plant alkaloid be found to provide a lissive action? In 1932, it seemed
probable to me that the selective lissive removal of spastic muscular rigidity was the
result of a mixture of two actions. This could presumably be brought about by one
alkaloid only ifthat alkaloid acted both peripherally (as a curare) and centrally (in the
manner of strychnine). In 1935, diaboline seemed to me to act in this way, its peri-
pheral action being still present, though weak, when its central action, after slow
absorption ofthe drug from blood to cerebrospinal fluid, in due course became effec-
tive. But diaboline was not lissive in spasticity, rather the reverse.
Unfortunately, different consignments of diaboline, as it was subsequently pre-
pared, have been found to have somewhat inconstant actions. Though this was not the
method used by Harold King in 1936,21 diaboline has more recently been prepared
from the Wieland-Gumlich aldehyde, which is a much more powerful centrally acting
agent than diaboline, as the following experiment shows.
In 1971, by the kindness of Professor W. Feldberg, pharmacologist to the Medical
Research Council, the Wieland-Gumlich aldehyde was compared with diaboline on a
cat preparation in which thedrugs wereadministered byperfusion through thecerebral
ventricles, or alternatively introduced by micro-injection into the grey matter of the
cerebral cortex in the hippocampal region. Using this method, the effect of both
diaboline and the Wieland-Gumlich aldehyde was to cause increased nervous excita-
tion and reflex response, in the same way as occurs with both strychnine and d-
40 G. B. Marini-Bettolo et al., Mart. Rend. Istituto Super. Sanita, 1954, 17: 851; and Gazz. Chim. Ital.,
1954,84: 1161.
41 H. Schmid, P. Waser, and P. Karrer, Helv. Chim. Acta, 1953, 36: 345.
42 R. Karrer and H. Schmid, Helvetica, 1958, 41: 1405.
43 D. Bovet, F. Bovet-Nitti, and G. B. Marini-Bettolo (editors), Curare and curare-like agents,
Amsterdam, Elsevier, 1959.
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tubocurarine when they are administered in this way. In these experiments, Professor
Feldberg was able to demonstrate that the Wieland-Gumlich aldehyde was twenty
times as strong as diaboline." The possibility of contamination of diaboline by the
aldehyde in the course ofits preparation must therefore be mentioned here: the former
was described as "95 per cent pure" when it was sent to me; and much ofall ofthe five
per cent impurity may have been due to the presence ofresidualaldehyde.'5 Itwouldbe
nice to have both the Wieland-Gumlich aldehyde and diaboline examined again, phar-
macologically, and more thoroughly than I was ever able to do.
There is, to my mind, encouragement for further experiment to be made with such
alkaloids of the toxiferine-strychnine series as are held up at the "blood-brain
barrier". This would be one possible approach to the task ofexploiting the interplay of
drugs acting upon the nervous system, with a view to clarifying the lissive action that
was found in some crude curares fifty years ago, but has not yet been traced to an
alkaloid, or alkaloids, ofany plant or plant mixture.
"Personal communication.
43 This supposition is confirmed by Hoffmann-La Roche, who have special experience in this field, in a
letter from Prof. A. Hirlimann to medated 20 October 1981.
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